

In Vivo Tumor Inhibitory Effects of Nutritional Rice Bran Supplement MGN-3/Biobran on Ehrlich Carcinoma-Bearing Mice*

Nariman K. Badr El-Din

Department of Zoology, Faculty of Science, University of Mansoura, Mansoura, Egypt

Eman Noaman

Department of Radiation Biology, National Center for Radiation and Technology, Cairo, Egypt

Mamdooh Ghoneum

Department of Otolaryngology, Drew University of Medicine and Science, 1621 E. 120th Street, Los Angeles, California, USA

This study was undertaken to investigate the in vivo anti-tumor activity of MGN-3/Biobran, a modified arabinoxylan rice bran. Swiss albino mice were inoculated intramuscularly in the right thigh with Ehrlich ascites carcinoma (EAC) cells. On Day 8, mice bearing a solid Ehrlich carcinoma (SEC) tumor were treated with MGN-3 via intraperitoneal injection. Tumor growth, cytokine production, and apoptotic effect of MGN-3 were examined. MGN-3 caused a highly significant delay in both tumor volume (63.27%) and tumor weight (45.2%) as compared to controls ($P < 0.01$). The mechanisms by which MGN-3 exerts its antitumor effect seem to involve its ability to induce apoptosis and immune modulation. MGN-3 induced a 1.8-fold increase in the percentage of apoptotic SEC cells as determined by flow cytometry and the histopathological examination. In addition, MGN-3 influenced plasma cytokine production by increasing the levels of tumor necrosis factor- α and interferon- γ , while downregulating levels of the immune suppressing cytokine interleukin-10. Data also showed that non-tumor-bearing mice intramuscularly injected with MGN-3 resulted in a twofold increase in natural killer activity. No adverse side effects due to MGN-3 treatment were observed; all animals displayed normal feeding/drinking and life activity patterns. These data may have clinical implications for the treatment of solid cancers.

INTRODUCTION

Cancer remains the largest cause of mortality in the world, claiming over 6 million lives each year (1). Anticancer drug therapies induce apoptosis in cancer cells but are mostly toxic,

immune-suppressive, mutagenic, and carcinogenic (2–5). Previous studies have shown that several natural agents possess antitumor activity including ginger derivatives (6), *Allium sativum* (garlic) (7,8), vitamin E (9), Chinese herbal preparation (PC SPES) (10), protein-bound polysaccharide K (11), and yeast (12–14). This investigation serves to introduce MGN-3/Biobran into this group of anticancer agents. MGN-3 is an arabinoxylan extracted from rice bran that has been treated enzymatically with Shiitake mushroom extracts (15). Previous reports have shown MGN-3 to be a potent biological response modifier (BRM) that stimulates several different arms of the immune system including natural killer (NK) cells (16–19), T cells (15), B cells (15), and macrophages (20). In addition, MGN-3 is capable of sensitizing human leukemic cell surface CD95 receptors that are involved in the triggering of apoptosis (21). In this study, we investigated the in vivo antitumor activity of MGN-3/Biobran and its effects on cytokine production and NK cell activity. Data from this study revealed that both intraperitoneal (IP) and intratumoral (IT) injections of MGN-3 into tumor-bearing mice result in significantly reduced tumor volume. The mechanisms supporting this phenomenon may involve the immunomodulatory and apoptotic functions of this product. These data may suggest clinical applicability of MGN-3 in the treatment of solid tumors.

MATERIALS AND METHODS

Animals

Female Swiss albino mice (2 mo old) weighing 19 to 21 g were housed 5 per cage at constant temperature ($24^{\circ}\text{C} \pm 2^{\circ}\text{C}$) with alternating 12-h light and dark cycles. Animals were provided with standard cube pellets and water ad libitum. The pellets consist of casein (12.5%), fats (1.0%), wheat flour (80%), bran (3.3%), olive oil (2.3%), dl-methionine (0.5%), vitamins and salt mixture (0.2%), and water (0.2%). The ratio of total

Submitted 29 January 2007; accepted in final form 7 May 2007.

*Data partially presented at AICR/WCRF International Research Conference on Food, Nutrition, and Cancer, Washington, July 2006.

Address correspondence to Nariman K. Badr El-Din, Department of Zoology, Faculty of Science, University of Mansoura, Mansoura, 35516 Egypt. Phone: 2010101-6511. E-mail: na_ri_eg@yahoo.com

calories was about 18% protein, 73% carbohydrate, and 9% fat. The pellets were purchased from Misr Oil & Soap Company (Cairo, Egypt). The actual food intake was monitored and found to be from 4 to 5 g/day/animal weighing $20 \text{ g} \pm 2 \text{ g}$.

Tumor Cell Lines

Two tumor cell lines were used in this study. Ehrlich ascites carcinoma (EAC) cells, kindly supplied by the National Cancer Institute, Cairo University, Egypt, were maintained by weekly IP transplantation of 2.5×10^6 cells. A yeast artificial chromosome-1 (YAC-1) cell line (a Moloney leukemia virus-induced mouse T-cell lymphoma of A/Sn mice origin) obtained from the American Type Culture Collection (ATCC, Rockville, MD) was acquired for use in NK activity assays.

Complete Medium (CM)

RPMI 1640 medium supplemented with 10% heat inactivated fetal calf serum, 2 mM glutamine, and 100 $\mu\text{g/ml}$ streptomycin and penicillin was used to maintain cell cultures.

MGN-3

MGN-3 is a processed hemicellulose that is obtained by reacting rice bran hemicelluloses with multiple carbohydrate hydrolyzing enzymes from shiitake mushrooms. The main chemical structure of MGN-3 is an arabinoxylan, with a xylose in its main chain and arabinose in its side chain (15). It contains polysaccharides (β 1, 3-glucan, and activated hemicellulose). To guarantee the purity and consistency of MGN-3 production from batch to batch, 9 parameters are measured, each by a specific method and specification (Table 1). In addition, the effective fraction of MGN-3/Biobran raw material is measured by the

TABLE 1
Analysis of MGN-3 from batch to batch

Parameter	Test method	Specification
Appearance	Organoleptic test	Light brown powder
Moisture	Loss on drying test	<8.0
Protein	Lowry method	8.0~15.0%
Ash	Dry ash method	5.0~10.0%
Carbohydrates	Anthrone method	65.0~80.0%
Arsenic (as As_2O_3)	DDTC-Ag method	<5.0 ppm
Heavy metals (as Pb)	Heavy metals limit test	<20.0 ppm
Aerobic plate count	Standard plate-count method	< 3.0×10^3 CFU/g
Coliform bacteria	Confirmation of gas production-BGLB broth	Negative

Abbreviations are as follows: DDTC, Diethyldithiocarbamate; CFU, colony forming units; BGLB, Brilliant Green Lactose Bile.

standard anthrone test (22). In the current study, MGN-3 dissolved in 0.9% saline was given to mice bearing solid Ehrlich carcinoma (SEC) via IP or IT injection [40 mg/kg body weight (BW)]. MGN-3 was provided by Daiwa Pharmaceuticals Co. Ltd. (Tokyo, Japan).

Experimental Design

Tumor transplantation and IP and IT injections of MGN-3. On Day 0, female Swiss albino mice were inoculated intramuscularly with 0.2 mL EAC cells (2.5×10^6 cells) in the right thigh of the lower limb. Posttumor cell inoculation, mice bearing a solid Ehrlich tumor mass of $\sim 100 \text{ mm}^3$ were randomly divided into 2 groups for IP treatment: 1) mice bearing solid tumors receiving IP injections of phosphate-buffered solution (PBS; $n = 13$) and 2) mice bearing solid tumors receiving IP injections of MGN-3 ($n = 13$). Similarly, IT-treated mice were randomly divided into 2 groups: 1) mice receiving IT injections of PBS ($n = 10$) and 2) mice receiving IT injections of MGN-3 ($n = 10$). A control group of tumor-free mice ($n = 8$) was included in each experiment to establish a baseline for all parameters under investigation. MGN-3 dosage was 40 mg/kg BW provided in a single 0.1 ml shot. Animals receiving IP injections commenced treatment on Day 8 post-EAC cells inoculation with continued treatment 3 times a week for 3 wk. Animals receiving IT injections commenced treatment on Day 11 post-EAC cell inoculation and continued treatment twice a week thereafter for 5 wk.

Tumor volume (TV) and tumor weight (TW) analysis. Time interval measurements of TV using digital Vernier calipers were conducted from Day 8 to Day 35 or Day 11 to Day 45 post-EAC cells inoculation. Data collected were plugged into the following formula to obtain tumor volume: $\text{TV} (\text{mm}^3) = 0.52 AB^2$, where A is the minor axis and B is the major axis. On Day 35, after receiving IP injections of MGN-3, mice were euthanized, and solid tumors were excised for TW determination, photographed for tumor regression, and processed for histopathological studies.

BW Changes

Animals bearing SEC treated IP with MGN-3 or PBS were examined for BW changes: (initial BW on Day 0, last and net final BWs on Day 35). Net final BW = (final BW – tumor weight). BW gain was determined as the difference between initial and net final BW.

Apoptosis as Determined by Flow Cytometry

Flow cytometry analysis was used to measure the percentage of apoptotic cancer cells in tumor bearing mice that were either IP treated with PBS or MGN-3. Dead cells were detected by fluorescein-conjugated Annexin V and propidium iodide technique (Annexin V-FITC apoptosis detection kit, BioVision Research Products, Mountain View, CA). Cells in suspension were prepared as described by Tribukait et al. (23). Cells were acquired by FACScan (Becton Dickinson, San Jose, CA) and analyzed by Cell-Quest software.

Histopathological studies. Histopathological studies were carried out to evaluate the apoptotic figures in the tumor-bearing mice treated IP with MGN-3 or PBS groups. The tumor tissues were fixed in 10% neutral buffered formalin for at least 24 h, processed for paraffin sections (4 μ m thick), and stained with hematoxylin and eosin (H&E). Sections were examined for apoptotic changes under a light microscope.

Cytokine Analysis

On Day 35 posttumor cells inoculation plasma was collected from 3 animal groups: tumor-free mice (control), tumor-bearing mice PBS treated, and tumor-bearing mice MGN-3 treated IP. Animals fasted for 16 h before sampling, and plasma was used to examine the levels of tumor necrosis factor-alpha (TNF- α), interferon-gamma (IFN- γ), and interleukin-10 (IL-10). Cytokine concentrations were measured via mouse cytokine specific enzyme-linked immunosorbent assay kits provided by CyImmune Sciences Inc. (Rockville, Maryland).

NK Cell Studies

Preparation of splenic cells. Non-tumor-bearing mice were injected daily with MGN-3 (100 μ g/ml) in the thigh. A total of 14 days posttreatment, mice were sacrificed by cervical dislocation. Spleens were removed, teased in CM, and contaminating erythrocytes were lysed with distilled water for 20 s at room temperature (27°C). Single cell suspensions were washed once with Hanks balanced salt solution (HBSS), and cells were resuspended to a concentration of 1×10^7 cells/ml CM. Cells were counted using a hemocytometer and a light microscope.

Measuring NK activity by ^{51}Cr -release assay. A standard Cr-release assay for measuring NK cell activity was employed as follows: YAC-1 tumor target cells (5×10^6) were labeled with 100 μ Ci of sodium chromate solution for 1 h in 0.1 ml CM. Tumor cells were washed 4 times in 5 ml HBSS, and 1×10^4 cells were pipetted into 96-well, round-bottomed Linbro plates (Linbro Chemical Co., Hamden, CT). Effector cells were pipetted into quadruplicate wells to give effector:target (E:T) ratios of 100:1, 50:1, 25:1, and 12.5:1. Following a 4-h incubation at 37°C, 0.1 ml of supernatant from each well was collected and counted in a gamma counter. The percentage of isotope released was calculated using the following formula:

$$\% \text{lysis} = \frac{\text{Exp. Rel.} - \text{Sp. Rel.} \times 100}{\text{Total Rel.} - \text{Sp. Rel.}}$$

where Sp. = spontaneous and exp =/experimental. In order to address variability in cell yield or recovery from different cell populations, the units of lytic capacity were used. Dose response curves for the populations were obtained by plotting the percentage of target cells killed on the y-axis and the E:T ratio on the x-axis. Lytic units (LUs) were then defined as the number of effector cells extrapolated from the dose response curve, with 1 LU corresponding to the number of effector cells

required to achieve 15% lysis (16). $\text{LU}/1 \times 10^7$ is the number of LUs in 10 million effector cells.

Effector-target cell conjugate assay. The capacity of splenic NK effector cells to form conjugates with YAC-1 target cells was measured in both the MGN-3-treated group and the control group as previously described (24). Splenic cells (1×10^5) were incubated with 5×10^5 target cells in 1 ml of CM. The cell mixture was pelleted at 130 g for 10 min and incubated for 1 h at 4°C. Pellets were gently resuspended, and cytocentrifuged smears were prepared and stained with Giemsa. The percentage of conjugates was determined by counting 200 lymphocytes (bound and free) in triplicate samples.

Adverse Effects of MGN-3 (Toxicity)

Mice were examined daily for adverse side effects by MGN-3 as assessed by changes in the normal feeding/drinking cycles and life activity patterns for the entire treatment period. Changes in BW were also recorded weekly.

Statistical Analysis

Cytokine values are reported as the mean \pm SE, and data were analyzed using one-way analysis of variance measures followed by post hoc tests for multiple comparisons. Statistical significance of other data was determined by Student's *t*-test. Differences were considered significant at the $P < 0.05$ level.

RESULTS

Adverse Effects of MGN-3 (Toxicity)

Animals were monitored to observe potential toxic side effects of MGN-3 treatment. No adverse side effects or unintentional deaths were observed during the treatment period (35 days). In addition, MGN-3 IP-treated mice showed a significant final BW gain.

TV

IP injection of MGN-3. Figure 1A shows that IP-administration of MGN-3 in tumor-bearing mice resulted in retardation of solid tumor development that became significant as early as Day 14 posttreatment. By Day 35, the percent TV differences between MGN-3 treated ($931.98 \text{ mm}^3 \pm 144.76$) and PBS-treated mice ($2537.11 \text{ mm}^3 \pm 143.52$) reached -63.27% ($P < 0.01$). Photographs of the tumor isolated from MGN-3-treated mice clearly demonstrate significant tumor regression as compared to PBS-treated mice. Similar levels of tumor regression were observed in all groups tested (Fig. 1B).

IT injection of MGN-3. IT injection was performed to examine an alternative route by which MGN-3 may exert an antitumor effect in vivo. Figure 2 shows that IT administration of MGN-3 suppressed tumor growth that began on Day 28 posttreatment. TV differences became significant on Day 36 when tumor delay reached -32.24% , $P < 0.05$. TV differences became highly significant when percent divergence between





FIG. 1. A: In vivo effect of intraperitoneal injection of MGN-3 on tumor volume. Mice were inoculated in the right thigh with Ehrlich ascites carcinoma cells. At Day 8, after tumor cells inoculation, mice bearing solid Ehrlich carcinoma were injected with MGN-3 (■) and change of tumor volume (TV) mm³ was examined at Day 8 until Day 35. The figure represents the change of TV mm³ during the time course; results were compared with control phosphate-buffered solution (PBS)-treated mice-bearing tumor (▲). Each value represents the mean ± SE. * *P* < 0.05, ** *P* < 0.01 as compared to PBS group at the corresponding time point. B: Photograph of tumor regression, PBS-treated and MGN-3-treated mice bearing tumor. Data is representative of all groups examined.

MGN-3-treated and PBS-treated tumor-bearing mice reached -44.83%, *P* < 0.01 on Day 45 of tumor cells inoculation.

g, representing a highly significant change (*P* < .01) in TW, a difference of 45.2%.

TW

Table 2 shows the effect of IP treatment with MGN-3 on TW examined at the end of the experiment on Day 35. The TW of PBS-treated mice was found to be 6.62 ± 0.38 g; on the other hand, the TW in MGN-3-treated group was 3.63 ± 0.45

BW

Changes in BW were examined during the 35 days of the experiment. As shown in Table 2, IP administration of MGN-3 to SEC-bearing mice caused a significant BW gain of +7.32%, *P* < 0.025.




FIG. 2. In vivo effect of intratumoral injection of MGN-3 on tumor volume. Mice were inoculated in the right thigh with Ehrlich ascites carcinoma cells. At Day 11, after tumor cells inoculation, mice bearing solid Ehrlich carcinoma were injected with MGN-3 twice a week for 5 wk at concentration of 40 mg/kg body weight (■). The change on total volume mm^3 was examined at Day 11 until Day 45, and results were compared with the phosphate-buffered solution (PPS)-treated tumor-bearing mice (▲). Each value represents the mean \pm SE. * $P < 0.05$, ** $P < 0.01$ as compared to PBS group at the corresponding time point.

Apoptosis of SEC

Flow cytometry. The data in Table 3 show the flow cytometry analysis of the percentage of apoptotic cells in SEC-bearing mice at Day 35 posttumor cell transplantation. PBS-treated tumor-bearing mice show $42.61 \pm 5.56\%$ apoptotic cells. IP treatment with MGN-3 significantly increased the percentage of apoptotic SEC cells ($74.68 \pm 4.22\%$). This represents a 1.8-fold ($P < 0.0001$) increase in the percentage of apoptotic SEC cells.

Histopathological examination. Histopathological sections were examined for the presence of apoptotic cells in tumor-bearing mice posttreatment IP with MGN-3. Figure 3A shows a marked increase in the number of apoptotic tumor cells in MGN-3-treated mice as compared with only a few scattered, individual apoptotic cells in the tumors of PBS-treated, SEC-bearing mice (Fig. 3B).

Cytokine Levels

The IP effects of MGN-3 treatment on the levels of plasma $\text{TNF-}\alpha$, $\text{IFN-}\gamma$, and IL-10 measured on Day 35 posttumor transplantation are shown in Table 4.

$\text{TNF-}\alpha$ plasma level. Data in Table 4 show no significant differences in the levels of $\text{TNF-}\alpha$ between the control tumor-free mice ($1,100 \text{ pg/ml} \pm 10.4$) and PBS-treated, tumor-bearing mice ($1,146 \text{ pg/ml} \pm 16$). However, the treatment of MGN-3 resulted in significantly elevated levels of $\text{TNF-}\alpha$ production

($1,271.9 \text{ pg/ml} \pm 13.5$, $P < 0.01$), approximately 11% higher than mice bearing SEC, and 15% higher than control.

$\text{IFN-}\gamma$ plasma level. PBS-treated, tumor-bearing mice showed insignificant differences in plasma $\text{IFN-}\gamma$ ($142.1 \text{ pg/ml} \pm 10.6$) when compared to the control tumor-free mice ($158.75 \text{ pg/ml} \pm 19.82$). Treatment with MGN-3 showed an enhancement in plasma $\text{IFN-}\gamma$ levels ($404.1 \text{ pg/ml} \pm 58.3$, $P < 0.01$) of 184.4% over PBS-treated, tumor-bearing mice, and 154.54% over control mice (Table 4).

IL-10 plasma levels. Data depicted in Table 4 illustrate that plasma concentrations of the immune-suppressing cytokine IL-10 dramatically increased by over twofold in PBS-treated, tumor-bearing mice ($858.5 \text{ pg/ml} \pm 140.9$, $P < 0.01$) as compared to the control tumor-free group ($405.5 \text{ pg/ml} \pm 25.0$, 111.71%). Administration of MGN-3 resulted in IL-10 plasma levels of $465.3 \text{ pg/ml} \pm 30.0$, similar levels to that of the tumor-free control group.

NK Cell Studies

NK activity. NK cell activity was examined 2 wk after daily intramuscular treatment with MGN-3. Using YAC-1 cells as targets, MGN-3-treated mice showed elevated NK cell activity as compared to control untreated mice at various E:T ratios (Fig. 4). A significant increase (twofold) between controls and MGN-3-treated mice was detected at each comparison ratio:

TABLE 2

Effect of IP injection of MGN-3 on the body weight (g) and tumor weight (g)^a

Group Parameters	Tumor-Bearing Mice	
	PBS	MGN-3
Initial Body weight (g) (at Day 0)		
Mean ± SE	20.21 ± 0.47	20.64 ± 0.51
No. of mice	13/13	13/13
Final Body weight (g) (at day 35)		
Mean ± SE	26.67 ± 0.58	25.78 ± 0.54
No. of mice	11/13	13/13
Tumor weight (g) (at day 35)		
Mean ± SE	6.62 ± 0.38	3.63 ± 0.45 ^b
Net final Body weight (g)		
Mean ± SE	20.05 ± 0.48	22.15 ± 0.63 ^c
Body weight gain (g)	-0.15 g	+1.51 g
% of change from the initial body weight	(-0.79%)	(+7.32%)

^aAbbreviations are as follows: IP, intraperitoneal; PBS, phosphate-buffered solution. Each value represents the mean ± SE of the corresponding number of animals/group. Net final body weight = (Final body weight at Day 35 - Tumor weight at Day 35). Body weight gain (Net final body weight - Initial body weight).

^bSignificant at $P < 0.01$ as compared to the PBS group.

^cSignificant at $P < 0.025$ as compared to the initial body weight.

from 2.7% to 5.5% at 12.5:1, 5.1% to 13.6% at 25:1, 8.4% to 17.4% at 50:1, and 10.6% to 22.1% at 100:1. When calculated in terms of LUs, statistical analysis showed a significant increase in NK cell activity in MGN-3 treated mice (27.1 LUs) as compared to controls (8.3 LUs, $P < 0.01$).

Percent conjugate formation. To examine whether MGN-3 treatment affects NK cell binding capacity to tumor cell targets,

TABLE 3

Effect of IP injection of MGN-3 on the percentage of apoptotic tumor cells in mice bearing solid ehrlich carcinoma as determined by flow cytometry at day 35 posttumor cells inoculation^a

Group Parameters	Tumor- Bearing Mice	
	PBS	MGN-3
% Apoptotic tumor cells		
Mean ± SE	42.61 ± 5.56%	74.68 ± 4.22%
% of Change from controls	—%	* 75.26%
Significance	—%	$P < 0.0001$
No. of mice	8	8


^aAbbreviations are as follows: IP, intraperitoneal; PBS, phosphate-buffered solution.

we compared the percentage of conjugate formation between NK cells obtained from either MGN-3-treated or control mice against YAC-1 tumor cells. As shown in Fig. 5, the proportion of conjugate-forming cells in MGN-3-treated mice was significantly higher (27.5%) as compared to control mice (14%, $P < 0.01$), representing a twofold increase.

DISCUSSION

In this study, we examined the effect of MGN-3 against tumor growth using SEC-bearing Swiss albino mice as a model. MGN-3 exhibited a potent antitumor effect in vivo as indicated by significant tumor regression post-IP and IT injection with MGN-3. The mechanisms by which MGN-3 exerts its antitumor effect seems to involve both immune-modulatory and apoptotic effects. With respect to tumor immunology, tumors

(A) MGN-3



(B) PBS




FIG. 3. Cross sections of solid Ehrlich carcinoma-bearing mice. A: Section of MGN-3-treated tumor demonstrates extensive apoptosis. B: Section of control tumor shows most of tumor cells are viable except for a few spots of apoptosis. ($\times 400$ magnification with hematoxylin and eosin stain; arrows point to apoptotic cells). PBS, phosphate-buffered solution.

TABLE 4

Effect of IP injection of MGN-3 on plasma cytokine levels in mice bearing solid ehrlich carcinoma on day 35 of tumor cells inoculation^a

Groups Parameters	Control mice (without tumor)	Tumor-Bearing Mice	
		PBS	MGN-3
TNF- α (pg/ml)			
Mean \pm SE	1,100 \pm 10.4	1,146 \pm 16	1,271.9 \pm 13.5 ^{c,d}
% Change ^b	—%	(4.17%)	(15.63%)
No. of mice	8	11	10
IFN- γ (pg/ml)			
Mean \pm SE	158.75 \pm 19.8	142.1 \pm 10.6	404.1 \pm 58.3 ^{c,d}
% change ^b	—%	-10.46%	154.54%
No. of mice	8	11	10
IL-10 (pg/ml)			
Mean \pm SE	405.5 \pm 25.0	858.5 \pm 140.9 ^c	465.3 \pm 30.0 ^d
% change ^b	—%	111.71%	14.75%
No. of mice	8	11	10

^aAbbreviations are as follows: IP, intraperitoneal ; PBS, phosphate-buffered solution; TNF- α , tumor necrosis factor-alpha; IFN- γ , interferon-gamma; IL-10, interleukin-10. Each value represents the mean \pm SE from the indicated number of mice.

^bPercent change as compared to control group.

^cSignificantly different from the control group at 0.01 level.

^dSignificantly different from the PBS tumor-bearing group at 0.01 level.

are characterized by their ability to avoid host immune system (25–27). An Ehrlich tumor is a rapidly growing carcinoma with very aggressive behavior. It can avoid host immune response by secreting a variety of immunosuppressive cytokines, resulting in the dysfunction of cytotoxic cell immuno-surveillance (25), which plays a role in controlling tumor growth (28,29). Indeed, observations demonstrating that an imbalance in the cytokine network is associated with tumor evolution established the basis for therapeutic approaches to modify cytokine production to favor tumor rejection (30).

Results presented here show that MGN-3 is a potent *in vivo* inducer of both TNF- α and IFN- γ , a finding that has been pre-

viously reported *in vitro* using human peripheral blood lymphocytes (19), macrophages, and macrophage cell lines (20). Both TNF- α and IFN- γ are known to present strong antitumor activities (31–33). Type I interferons (IFN- α and IFN- β) are used for the treatment of hepatocellular carcinoma (34–36). Type I IFNs activate NK cells (37) and cytolytic T lymphocytes (38,39) via increased production of IL-1, IL-6, and TNF- α (40–42). Additionally, MGN-3 downregulates the tumor-induced increase in plasma levels of the immunosuppressive cytokine IL-10, which has been shown to inhibit the synthesis of several cytokines including IL-2 and IL-3 in Th1 cells (43,44), IL-4 and IL-5 in Th2 cells (30), and TNF- α and IFN- γ in NK cells (45,46).




FIG. 4. *In vivo* effect of MGN-3 on natural killer (NK) activity. Non-tumor-bearing mice were treated with MGN-3 for 2 wk, and splenic NK activity was measured by means of a 4-h Cr-release assay and is expressed at different effector:target (E:T) ratios and as number of lytic units (LUs). Data represent the mean \pm SD of 3 mice/group. * $P < 0.01$ as compared to control untreated mice.




FIG. 5. Extent of conjugates of YAC-1 target cells by natural killer (NK) cells from non-tumor-bearing mice treated with MGN-3. Effector cells were isolated from control and MGN-3-treated mice. * $P < 0.01$ as compared to control untreated mice.

Another mechanism by which MGN-3 is able to cause tumor regression is the induction of cancer cell apoptosis via its immunomodulatory effects on NK cells and cytokine production. NK cells play an important role in immune surveillance against cancer (46–48), and have been shown to kill target cells including tumor cells via different pathways, such as the ligation of FasL to its Fas receptor to induce apoptosis (49–52). Earlier studies have shown that oral administration of MGN-3 in normal humans (17,19) and cancer patients (18) and IP administration of MGN-3 in aged mice (16) resulted in activation of NK cells. Data from this study further support these studies by demonstrating activation of murine NK cells postintramuscular treatment with MGN-3 in the thigh of Swiss albino mice. It is of interest to note that Takahara and Sano (53) demonstrated that the oral administration of MGN-3 in cancer patients treated with chemotherapy led to an enhancement of NK cell activity, which correlated with an increased life expectancy as compared to patients treated with chemotherapy alone.

Similarly, MGN-3 may exert an apoptotic effect via increased production of TNF- α and IFN- γ . Type I IFNs act to elicit cell-cycle arrest and apoptosis (54–56), and IFN- γ and TNF- α have been shown to act synergistically to induce cancer cell death via apoptotic and necrotic effects (57,58). Additionally, MGN-3 has been shown to sensitize human leukemic cell surface CD95 receptors that are involved in the triggering of apoptosis (21), suggesting that this natural product may play a direct role in solid tumor apoptosis.

Anticancer therapeutic agents induce apoptosis in cancer cells; however, they remain mostly toxic (2–5). Similarly, BRMs used for immunomodulation including IL-2, IL-12, IL-15, and interferons (59–63) have had limited success due to toxicity. Therefore, the need for a new BRM with minimal side effects is greatly warranted. MGN-3 is a natural product that possesses no known side effects. In conclusion, the results of this study yield important information about the ability of MGN-3 to cause a rapid and significant tumor regression in mice. The effect appears to involve the immunomodulatory and apoptotic capabilities of MGN-3. This data may establish the foundation for in vivo studies that could have therapeutic implications.

ACKNOWLEDGMENT

We thank Daiwa Pharmaceutical Co. LTD, Tokyo, Japan, for the financial support of this project.

REFERENCES

1. Abdullaev FI, Rivera-Luna R, Roitenburd-Belacortu V, and Espinosa-Aguirre J: Pattern of childhood cancer mortality in Mexico. *Arch Med Res* **31**, 526–531, 2000.
2. Marty M, Mignot L, Gisselbrecht G, Morvan F, Gorins A, et al.: Teratogenic and mutagenic risks of radiotherapy: when and how to prescribe contraception. *Contracept Fertil Sex (Paris)* **13**(1Suppl), 181–186, 1985.
3. Mills KH, Greally JF, Temperley IJ, and Mullins GM: Haematological and immune suppressive effects of total body irradiation in the rat. *Ir J Med Sci* **149**, 201–208, 1980.
4. Sanderson BJ, Ferguson LR, and Denny WA: Mutagenic and carcinogenic properties of platinum-based anticancer drugs. *Mutat Res* **355**, 59–70, 1996.
5. Santin AD, Hermonat PL, Ravaggi A, Bellone S, Roman J, et al.: Effects of concurrent cisplatin administration during radiotherapy vs. radiotherapy alone on the immune function of patients with cancer of the uterine cervix. *Int J Radiat Oncol Biol Phys* **48**, 997–1006, 2000.
6. Lee E and Surh YJ: Induction of apoptosis in HL-60 cells by pungent vanilloids, [6]-gingerol and [6]-paradol. *Cancer Lett* **134**, 163–168, 1998.
7. Lamm DL and Riggs DR: The potential application of *Allium sativum* (garlic) for the treatment of bladder cancer. *Urol Clin North Am* **27**, 157–162, xi, 2000.
8. Fleischauer AT, Poole C, and Arab L: Garlic consumption and cancer prevention: meta-analyses of colorectal and stomach cancers. *Am J Clin Nutr* **72**, 1047–1052, 2000.
9. Sigounas G, Anagnostou A, and Steiner M: dl-alpha-tocopherol induces apoptosis in erythroleukemia, prostate, and breast cancer cells. *Nutr Cancer* **28**, 30–35, 1997.
10. Halicka D, Ardelt B, Juan G, Mittelman A, and Chen S: Apoptosis and cell cycle effects induced by extracts of the Chinese herbal preparation PC SPES. *Int J Oncol* **11**, 437–448, 1997.
11. Hattori TS, Komatsu N, Shichijo S, and Itoh K: Protein-bound polysaccharide K induced apoptosis of the human Burkitt lymphoma cell line, Namalwa. *Biomed Pharmacother* **58**, 226–230, 2004.
12. Ghoneum M and Gollapudi S: Induction of apoptosis in breast cancer cells by *Saccharomyces cerevisiae*, the baker's yeast, in vitro. *Anticancer Res* **24**, 1455–1463, 2004.
13. Ghoneum M, Hamilton J, Brown J, and Gollapudi S: Human squamous cell carcinoma of the tongue and colon undergoes apoptosis upon phagocytosis

- of *Saccharomyces cerevisiae*, the baker's yeast, in vitro. *Anticancer Res* **25**, 981–989, 2005.
14. Ghoneum M and Gollapudi S: Modified arabinoxylan rice bran (MGN-3/BioBran) enhances yeast-induced apoptosis in human breast cancer cells in vitro. *Anticancer Res* **25**, 859–870, 2005.
 15. Ghoneum M: Anti-HIV activity in vitro of MGN-3, an activated arabinoxylan from rice bran. *Biochem Biophys Res Commun* **243**, 25–29, 1998.
 16. Ghoneum M and Abedi S: Enhancement of natural killer cell activity of aged mice by modified arabinoxylan rice bran (MGN-3/BioBran). *J Pharm Pharmacol* **56**, 1581–1588, 2004.
 17. Ghoneum M: Enhancement of human natural killer cell activity by modified arabinoxylan from rice bran (MGN-3). *Int J Immunother* **14**, 89–99, 1998.
 18. Ghoneum M and Brown J: NK immunorestitution of cancer patients by MGN-3, a modified arabinoxylan rice bran (study of 32 patients followed for up to 4 years). In *Anti-aging Medical Therapeutics, Volume III*, Klatz R, Goldman R (eds). Marina del Rey, CA: Health Quest Publications, 1999, pp. 217–226.
 19. Ghoneum M and Jewett A: Production of tumor necrosis factor-alpha and interferon-gamma from human peripheral blood lymphocytes by MGN-3, a modified arabinoxylan from rice bran, and its synergy with interleukin-2 in vitro. *Cancer Detect Prev* **24**, 314–324, 2000.
 20. Ghoneum M and Matsuura M: Augmentation of macrophage phagocytosis by modified arabinoxylan rice bran (MGN-3/bioBran). *Int J Immunopathol Pharmacol* **17**, 283–292, 2004.
 21. Ghoneum M and Gollapudi S: Modified arabinoxylan rice bran (MGN-3/BioBran) sensitizes human T cell leukemia cells to death receptor (CD95)-induced apoptosis. *Cancer Lett* **201**, 41–49, 2003.
 22. Quanhong L, Caili F, Yukui R, Guanghui H, and Tongyi C: Effects of protein-bound polysaccharide isolated from pumpkin on insulin in diabetic rats. *Plant Foods Hum Nutr* **60**, 13–16, 2005.
 23. Tribukait B, Moberger G, and Zetterberg A: Methodological aspects of rapid flow cytometry for DNA analysis of human urinary bladder cells. In *Pulse-Cytophotometry, Part I*. Ghent, Belgium: European press, Medicon, 1975, pp. 50–60.
 24. Itoh K, Suzuki R, Umezumi Y, Hanaumi K, and Kumagai K: Studies of murine large granular lymphocytes: II. tissue, strain, and age distributions of LGL and LAL. *J Immunol* **129**, 395–405, 1982.
 25. Segura JA, Barbero LG, and Marquez J: Ehrlich ascites tumour unbalances splenic cell populations and reduces responsiveness of T cells to *Staphylococcus aureus* enterotoxin B stimulation. *Immunol Lett* **74**, 111–115, 2000.
 26. Piemonti L, Zerbi A, and Di Carlo V: Strategies for tumor immune escape. *Drugs Today (Barc)* **39**, 701–724, 2003.
 27. Queiroz ML, Valadares MC, Bincoletto C, and Dieamant GC: Ehrlich ascites tumor as a tool in the development of compounds with immunomodulatory properties. *Immunopharmacol Immunotoxicol* **26**, 511–525, 2004.
 28. Herberman RB: Natural killer (NK) cells and their possible roles in resistance against disease. *Clin Immunol Rev* **1**, 1–65, 1981.
 29. Roder JC and Pross HF: The biology of the human natural killer cell. *J Clin Immunol* **2**, 249–263, 1982.
 30. Contasta I, Berghella AM, Pellegrini P, and Adorno D: Passage from normal mucosa to adenoma and colon cancer: alteration of normal sCD30 mechanisms regulating TH1/TH2 cell functions. *Cancer Biother Radiopharm* **18**, 549–557, 2003.
 31. Baron S, Tying SK, Fleischmann WR Jr, Coppenhaver DH, Niesel DW, et al.: The interferons. Mechanisms of action and clinical applications. *JAMA* **266**, 1375–1383, 1991.
 32. Cha SS, Kim MS, Choi YH, Sung BJ, Shin NK, et al.: 2.8 A resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity. *Immunity* **11**, 253–261, 1999.
 33. Borish LC and Steinke JW: 2. Cytokines and chemokines. *J Allergy Clin Immunol* **111**(2 Suppl), S460–S475, 2003.
 34. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, et al.: Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. *Lancet* **346**, 1051–1055, 1995.
 35. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, et al.: Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy. *Ann Intern Med* **131**, 174–181, 1999.
 36. Kashiwagi K, Furusyo N, Kubo N, Nakashima H, Nomura H, et al.: A prospective comparison of the effect of interferon-alpha and interferon-beta treatment in patients with chronic hepatitis C on the incidence of hepatocellular carcinoma development. *J Infect Chemother* **9**, 333–340, 2003.
 37. Biron CA, Nguyen KB, Pien GC, Cousens LP, and Salazar-Mather TP: Natural killer cells in antiviral defense: function and regulation by innate cytokines. *Annu Rev Immunol* **17**, 189–220, 1999.
 38. von Hoegen P: Synergistic role of type I interferons in the induction of protective cytotoxic T lymphocytes. *Immunol Lett* **47**, 157–162, 1995.
 39. Hiroishi K, Tuting T, and Lotze MT: IFN-alpha-expressing tumor cells enhance generation and promote survival of tumor-specific CTLs. *J Immunol* **164**, 567–572, 2000.
 40. Ohzato H, Monden M, Yoshizaki K, Ogata A, Nishimoto N, et al.: Systemic production of interleukin-6 following acute inflammation. *Biochem Biophys Res Commun* **197**, 1556–1562, 1993.
 41. Kawakami Y, Hayashi J, Ueno K, Ohmiya M, Kishihara Y, et al.: Elevation of serum soluble interleukin-2 receptor levels in patients with hepatitis C virus infection. *Fukuoka Igaku Zasshi* **88**, 274–282, 1997.
 42. Furusyo N, Hayashi J, Ohmiya M, Sawayama Y, Kawakami Y, et al.: Differences between interferon-alpha and -beta treatment for patients with chronic hepatitis C virus infection. *Dig Dis Sci* **44**, 608–617, 1999.
 43. Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, et al.: IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. *J Immunol* **146**, 3444–3451, 1991.
 44. Fiorentino DF, Bond MW, and Mosmann TR: Two types of mouse T helper cell: IV. th2 clones secrete a factor that inhibits cytokine production by Th1 clones. *J Exp Med* **170**, 2081–2095, 1989.
 45. Hsu DH, de Waal Malefyt R, Fiorentino DF, Dang MN, Vieira P, et al.: Expression of interleukin-10 activity by Epstein-Barr virus protein BCRF1. *Science* **250**, 830–832, 1990.
 46. Hsu DH, Moore KW, and Spits H: Differential effects of IL-4 and IL-10 on IL-2-induced IFN-gamma synthesis and lymphokine-activated killer activity. *Int Immunol* **4**, 563–569, 1992.
 47. Whiteside TL and Herberman RB: The role of natural killer cells in immune surveillance of cancer. *Curr Opin Immunol* **7**, 704–710, 1995.
 48. Herberman RB: Cancer immunotherapy with natural killer cells. *Semin Oncol* **29**(7Suppl), 27–30, 2002.
 49. Wu J and Lanier LL: Natural killer cells and cancer. *Adv Cancer Res* **90**, 27–56, 2003.
 50. Arase H, Arase N, and Saito T: Fas-mediated cytotoxicity by freshly isolated natural killer cells. *J Exp Med* **181**, 1235–1238, 1995.
 51. Velthuis JH, Gavric Z, de Bont HJ, and Nagelkerke JF: Impaired activation of caspases and prevention of mitochondrial dysfunction in the metastatic colon carcinoma CC531s-m2 cell line. *Biochem Pharmacol* **69**, 463–471, 2005.
 52. Walczak H and Krammer PH: The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. *Exp Cell Res* **256**, 58–66, 2000.
 53. Takahara K and Sano K: The life prolongation and QOL improvement effect of rice bran arabinoxylan derivative (MGN-3, BioBran) for progressive cancer. *Clin Pharmacol Ther* **14**, 267–271, 2004.
 54. Meurs EF, Galabru J, Barber GN, Katze MG, and Hovanessian AG: Tumor suppressor function of the interferon-induced double-stranded RNA-activated protein kinase. *Proc Natl Acad Sci USA* **90**, 232–236, 1993.
 55. Yano H, Iemura A, Haramaki M, Ogasawara S, Takayama A, et al.: Interferon alpha receptor expression and growth inhibition by interferon alpha in human liver cancer cell lines. *Hepatology* **29**, 1708–1717, 1999.

56. Murphy D, Detjen KM, Welzel M, Wiedenmann B, and Rosewicz S: Interferon-alpha delays S-phase progression in human hepatocellular carcinoma cells via inhibition of specific cyclin-dependent kinases. *Hepatology* **33**, 346–356, 2001.
57. Suk K, Kim YH, Chang I, Kim JY, Choi YH, et al.: IFNalpha sensitizes ME-180 human cervical cancer cells to TNFalpha-induced apoptosis by inhibiting cytoprotective NF-kappaB activation. *FEBS Lett* **495**, 66–70, 2001.
58. Sasagawa T, Hlaing M, and Akaike T: Synergistic induction of apoptosis in murine hepatoma Hepa1-6 cells by IFN-gamma and TNF-alpha. *Biochem Biophys Res Commun* **272**, 674–680, 2000.
59. Konjevic G, Jovic V, Jurisic V, Radulovic S, Jelic S, et al.: IL-2-mediated augmentation of NK-cell activity and activation antigen expression on NK- and T-cell subsets in patients with metastatic melanoma treated with interferon-alpha and DTIC. *Clin Exp Metastasis* **20**, 647–655, 2003.
60. Smyth MJ, Taniguchi M, and Street SE: The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent. *J Immunol* **165**, 2665–2670, 2000.
61. Carson WE, Fehniger TA, Haldar S, Eckhert K, Lindemann MJ, et al.: A potential role for interleukin-15 in the regulation of human natural killer cell survival. *J Clin Invest* **99**, 937–943, 1997.
62. Allavena P, Giardina G, Sen S, Colella G, Brogginini M, et al.: IFN-beta partially counteracts inhibition of natural killer activity induced by some antitumor agents. *J Interferon Cytokine Res* **18**, 87–93, 1998.
63. Appasamy R, Bryant J, Hassanein T, Van Thiel DH, and Whiteside TL: Effects of therapy with interferon-alpha on peripheral blood lymphocyte subsets and NK activity in patients with chronic hepatitis C. *Clin Immunol Immunopathol* **73**, 350–357, 1994.